Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece

• 主要な著者: Georgia Ragia (著者), Anthi Maslarinou (著者), Natalia Atzemian (著者), Eirini Biziota (著者), Triantafyllia Koukaki (著者), Charalampia Ioannou (著者), Ioanna Balgkouranidou (著者), George Kolios (著者), Stylianos Kakolyris (著者), Nikolaos Xenidis (著者), Kyriakos Amarantidis (著者), Vangelis G. Manolopoulos (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2023-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism. DPYD gene variants seriously affect DPD activity and are well validated predictors of FP-associated toxicity. DPYD variants rs3918290, rs55886062,...